ABBV

Company financials

AbbVie

Health Care Biotechnology North Chicago, Illinois Last filing Feb 20, 2026 · FY2025

                    Revenue
                    FY2025
                
$61.2B
                    3y CAGR +1.8%
                    
                    P27
                    
                    +8.6%
                    
                    Net income
                    FY2025
                
$4.2B
                    Net margin +6.9%
                    
                    P32
                    
                    -1.2%
                    
                    Total assets
                    FY2025
                
$134.0B
                    ROA +3.2%
                    
                    P27
                    
                    -0.9%
                    
                    Operating cash flow
                    FY2025
                
$19.0B
                    FCF margin +29.1%
                    
                    P96
                    
                    +1.2%

15 yrs · FY2011–FY2025 9 filed · 0 derived · 0 blank

1Y 3Y 5Y 10Y

Dollars % of revenue % of assets YoY % CAGR

Year-over-year change per cell; first column has no prior.

Balance Sheet

Assets, liabilities, and equity

28 accounts · 5 years

Total assets $134.0B

Total liabilities $43.3B

Shareholders equity $-3.3B

Account	2025	2024	2023	2022	2021
Assets
Cash and Cash Equivalents	-5.3%	-56.9%	+39.3%	-5.6%	—
Accounts Receivable	+15.3%	-2.1%	-0.9%	+12.8%	—
Inventory	+18.4%	+2.0%	+14.5%	+14.4%	—
Prepaid Expenses	+27.2%	-0.1%	+12.1%	-11.9%	—
Other Current Assets	+17.3%	+7.4%	+52.8%	+14.1%	—
Total Current Assets	+13.6%	-22.5%	+15.9%	+1.9%	—
Property,Plant and Equipment	+9.6%	+2.9%	+1.1%	-3.4%	—
Goodwill	+2.0%	+8.2%	+0.4%	-0.7%	—
Intangible Assets	-12.4%	+8.0%	-17.5%	-11.2%	—
Long Term Investments	-3.9%	-8.2%	+26.1%	-13.0%	—
Other Noncurrent Assets	+17.3%	+7.4%	+52.8%	+14.1%	—
Total Assets	-0.9%	+0.3%	-2.9%	-5.3%	—
Liabilities
Accounts Payable	+1079.4%	-20.1%	+25.7%	+1.8%	—
Accrued Liabilities	+421.7%	+3.4%	+10.6%	-11.5%	—
Current Portion of Long Term Debt	—	—	-100.0%	-92.9%	—
Other Current Liabilities	+8.1%	-6.8%	+5.5%	+6.8%	—
Total Current Liabilities	+11.7%	+2.4%	+28.1%	-16.1%	—
Deferred Tax Liabilities	-7.4%	+32.1%	-10.9%	-27.2%	—
Other Noncurrent Liabilities	+8.1%	-6.8%	+5.5%	+6.8%	—
Total Liabilities	+11.7%	+2.4%	+28.1%	-16.1%	—
Equity
Common Stock	+0.0%	+0.0%	+0.0%	+0.0%	—
Additional Paid In Capital	+5.4%	+5.7%	+4.9%	+5.1%	—
Retained Earnings	-96.1%	-690.0%	-120.9%	+53.0%	—
Treasury Stock	+11.5%	+25.5%	+42.2%	+46.2%	—
Accumulated Other Comprehensive Income	+40.6%	+16.5%	-4.8%	+24.1%	—
Noncontrolling Interest	+7.7%	+5.4%	+12.1%	+17.9%	—
Total Stockholders Equity	-198.3%	-67.9%	-40.0%	+12.0%	—
Total Liabilitiesand Equity	-0.9%	+0.3%	-2.9%	-5.3%	—

Income Statement

Revenue, expense, and profitability

19 accounts · 5 years

Revenue $61.2B

Operating income $15.1B

Net income $4.2B

Account	2025	2024	2023	2022	2021
IncomeStatement
Revenues Total Revenue	+8.6%	+3.7%	-6.4%	+3.3%	—
Expenses Cost of Revenue	+7.7%	-17.2%	+17.2%	-0.2%	—
Expenses Research and Development	-28.9%	+66.7%	+17.9%	-6.0%	—
Expenses Selling,General and Administrative	-5.0%	+14.6%	-15.6%	+23.6%	—
Expenses Depreciation and Amortization	-3.2%	-4.1%	+3.3%	-0.4%	—
Expenses Share Based Compensation	+4.8%	+22.0%	+11.3%	-3.0%	—
Expenses Operating Expenses	-2.4%	+13.6%	+4.1%	+4.3%	—
Other Income Expense Operating Income	+65.0%	-28.4%	-29.6%	+1.1%	—
Other Income Expense Interest Income	-59.0%	+20.0%	+190.3%	+376.9%	—
Other Income Expense Interest Expense	+3.0%	+26.3%	-0.3%	-8.0%	—
Other Income Expense Other Income/expense	-78.8%	+30.7%	-91.1%	+2.1%	—
Other Income Expense Income Before Tax	+77.5%	-40.5%	-53.6%	+3.8%	—
Income Tax Income Tax Expense	+514.7%	-141.4%	-15.6%	+13.3%	—
net Income net Income	-1.2%	-12.0%	-58.9%	+2.5%	—
net Income Comprehensive Income	+7.5%	-2.1%	-62.1%	+6.6%	—
Earnings Per Share Basic Eps	-1.2%	-12.1%	-58.9%	+2.6%	—
Earnings Per Share Diluted Eps	-1.3%	-12.1%	-59.0%	+2.8%	—
Earnings Per Share Weighted Average Shares Basic	+0.0%	+0.1%	-0.2%	+0.1%	—
Earnings Per Share Weighted Average Shares Diluted	+0.0%	+0.0%	-0.3%	+0.1%	—

Cash Flow Statement

Operating, investing, and financing flows

22 accounts · 5 years

Operating cash flow $19.0B

Investing cash flow $-6.6B

Financing cash flow $-12.7B

Account	2025	2024	2023	2022	2021
CashFlow
Operating Activities net Income	-1.2%	-12.0%	-58.9%	+2.5%	—
Operating Activities Depreciation and Amortization	-0.3%	+1.6%	-3.3%	-3.1%	—
Operating Activities Stock Based Compensation	+4.8%	+22.0%	+11.3%	-3.0%	—
Operating Activities Deferred Income Taxes	+66.0%	+49.8%	-49.6%	-115.0%	—
Operating Activities Changes In Operating Assets and Liabilities	+1124.5%	-146.2%	-77.6%	+44.9%	—
Operating Activities net Cash From Operating Activities	+1.2%	-17.7%	-8.4%	+9.5%	—
Investing Activities Capital Expenditures	+24.6%	+25.4%	+11.8%	-11.7%	—
Investing Activities Business Acquisitions	-98.8%	—	-100.0%	-51.4%	—
Investing Activities Purchases of Investments	-52.1%	-5.2%	-94.6%	+1108.4%	—
Investing Activities Other Investing Activities	+115.3%	-1353.8%	+98.3%	-111.5%	—
Investing Activities net Cash From Investing Activities	+68.1%	-936.3%	-222.5%	+73.4%	—
Financing Activities Proceeds From Debt	-76.5%	—	—	+100.0%	—
Financing Activities Repayment of Debt	-44.1%	—	—	—	—
Financing Activities Repurchase of Common Stock	-42.6%	-13.4%	+32.6%	+59.2%	—
Financing Activities Dividends Paid	+5.7%	+4.6%	+4.9%	+8.4%	—
Financing Activities Proceeds From Stock Issuance	-19.6%	+18.9%	-31.3%	+7.4%	—
Financing Activities Other Financing Activities	+19.3%	+18.8%	+60.0%	+25.0%	—
Financing Activities net Cash From Financing Activities	-144.2%	+69.7%	+30.6%	-30.3%	—
Cash Reconciliation Effect of Exchange Rate On Cash	+164.6%	-1400.0%	+108.1%	+36.1%	—
Cash Reconciliation net Change In Cash	+96.0%	-301.8%	+762.9%	-142.0%	—
Cash Reconciliation Cash At Beginning of Period	-5.3%	-56.9%	+39.3%	-5.6%	—
Cash Reconciliation Cash At End of Period	-5.3%	-56.9%	+39.3%	-5.6%	—

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 5 years

Ratio	2025	2024	2023	2022	2021
Profitability
Gross margin	+70.2%	+70.0%	+62.4%	+70.0%	+69.0%
Operating margin	+24.6%	+16.2%	+23.5%	+31.2%	+31.9%
Net margin	+6.9%	+7.6%	+9.0%	+20.4%	+20.5%
FCF margin	+29.1%	+31.7%	+40.6%	+41.8%	+39.1%
Growth
Revenue CAGR (3y)	+1.8%	+0.1%	+5.8%	+20.4%	+19.7%
Returns
ROE	-129.2%	+128.7%	+46.9%	+68.6%	+74.9%
ROA	+3.2%	+3.2%	+3.6%	+8.5%	+7.9%
ROIC	-161.2%	—	—	+197.7%	+280.8%
Liquidity
Current ratio	0.67x	0.66x	0.87x	0.96x	0.79x
Quick ratio	0.41x	0.42x	0.63x	0.69x	0.56x
Leverage
D/E	-13.24x	11.65x	3.65x	1.71x	2.28x
Interest coverage	5.21x	3.25x	5.74x	8.12x	7.40x
Efficiency
Asset turnover	0.46x	0.42x	0.40x	0.42x	0.38x
Cash conversion cycle	-522d	+97d	+82d	+84d	+70d

Valuation

Price against fundamentals

ABBV $218 · 2025-09-12 · 368d old · FY2025

Market cap $387.1B

P/E 91.60x

P/S 6.33x

P/B —

EV $384.4B

EV/EBITDA 17.12x

FCF yield +4.6%

Dividend yield +3.0%

Notes

Your annotations

Not watched

AbbVie

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Recent price history